Heidelberg 2022 – scientific programme
Parts | Days | Selection | Search | Updates | Downloads | Help
ST: Fachverband Strahlen- und Medizinphysik
ST 8: Radiation therapy II
ST 8.3: Talk
Thursday, March 24, 2022, 11:30–11:45, ST-H4
A combination of Brachy- and X-ray-therapy as a novel concept for intraocular tumors — •Henning Manke1, Dirk Flühs2, Justine Gemmecke1, Saskia Müller1, Michelle Stroth1, and Bernhard Spaan1 — 1Experimental Physics 5, TU Dortmund — 2Department of Radiotherapy, Essen University Hospital
Eye plaque brachytherapy with the beta emitter Ruthenium-106 is applied to a large fraction of ocular tumors. Due to the emitted particles' steep dose gradient, there is a limitation to the clinically treatable tumor height. Depending on the indications, eyes affected by a tumor larger than the maximum height have to be enucleated in many cases, especially if located close to the posterior pole. As this massively impairs the patients' quality of life, a novel concept to treat such tumors is currently investigated.
External photon irradiation through insensitive parts of the eye can be used to enhance the applied dose at the tumor apex. A confocal irradiation concept results in a low exposure of healthy tissue while the tumor control dose can be reached in all parts of the target volume. The X-ray therapy can be performed while the Ruthenium-plaque is positioned on the eye. Therefore the plaque itself, which is mainly made of silver, can be used as a beam stopper. This leads to an additional significant reduction of dose in the healthy tissue behind the tumor.
This contribution presents the general concept of the combined therapy, our methods to examine the physical and radiobiological properties and first results.